share_log

HC Wainwright & Co. Initiates Coverage On Arcutis Biotherapeutics With Buy Rating, Announces Price Target of $19

HC Wainwright & Co. Initiates Coverage On Arcutis Biotherapeutics With Buy Rating, Announces Price Target of $19

HC Wainwright & Co. 對Arcutis Biotherapeutics啓動了覆蓋,給予買入評級,並宣佈目標價格爲19美元。
Benzinga ·  2024/12/30 19:54  · 評級/大行評級

HC Wainwright & Co. analyst Douglas Tsao initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy rating and announces Price Target of $19.

HC Wainwright & Co. 分析師道格拉斯·曹以買入評級啓動了對Arcutis Biotherapeutics(納斯達克股票代碼:ARQT)的報道,並宣佈目標股價爲19美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論